Canadian Business -- WALTHAM, Mass. (AP) - Repligen Corp. said Monday that a mid-stage clinical trial showed one of its drug candidates was no more effective than a placebo in treating bipolar depression. The results sent Repligen shares tumbling more than 25 percent in morning trading.